These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 11842397)

  • 21. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is the role of maintenance rituximab in follicular NHL?
    Maloney DG
    Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New treatment approaches to indolent non-Hodgkin's lymphoma.
    Seymour JF
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
    Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C
    J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.
    Maloney DG; Press OW
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 8):63-76. PubMed ID: 9830635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab-induced tumor progression: does it really happen?
    Ozguroglu M; Turna H
    Med Oncol; 2004; 21(2):205-6. PubMed ID: 15299193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials.
    Horning JS
    Semin Hematol; 2000 Oct; 37(4 Suppl 7):27-33. PubMed ID: 11147487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical and phase I and II trials of rituximab.
    Maloney DG
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):74-8. PubMed ID: 10561021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Dallaire BK; Varns CL; Shen CD; Wei A; Leonard JE; McClure A; Weaver R; Cairelli S; Rosenberg J
    Curr Pharm Biotechnol; 2000 Jul; 1(1):1-9. PubMed ID: 11467356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical status and optimal use of rituximab for B-cell lymphomas.
    McLaughlin P; White CA; Grillo-López AJ; Maloney DG
    Oncology (Williston Park); 1998 Dec; 12(12):1763-9; discussion 1769-70, 1775-7,. PubMed ID: 9874849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.
    Wilson WH; Gutierrez M; O'Connor P; Frankel S; Jaffe E; Chabner BA; Grossbard ML
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):41-7. PubMed ID: 11842388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA approves new kind of lymphoma treatment. Food and Drug Administration.
    James JS; Dubs G
    AIDS Treat News; 1997 Dec; (No 284):2-3. PubMed ID: 11364912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
    Bhat SA; Czuczman MS
    Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab in indolent lymphoma: the single-agent pivotal trial.
    McLaughlin P; Hagemeister FB; Grillo-López AJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):79-87. PubMed ID: 10561022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.